Interactions Between Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase

References

1. Balzarini J., Karlsson A., Vandamme A. -M., Pérez-Pérez M. -J., Zhang H., Vrang L., Öberg B., Bäckbro K., Unge T., San-Félix A., Veläzquez S., Camarasa M. -J., Declercq E. 1993; Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(fort-butyl- dimethylsilyl)-3′-spiro-5′′-(4′′-amino-l′′,2′′-oxathiole-2″,2″-dioxide)]-β-d-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proceedings of the National Academy of Sciences U.S.A.: 906952–6956
   [Google Scholar]
2. Boucher C. A. B., Tersmette M., Lange J. M. A., Kellam P., Degoede R. E. Y., Mulder J. W., Darby G., Goudsmit J., Larder B. A. 1990; Zidovudine sensitivity of human immuno-deficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 336:585–590
   [Google Scholar]
3. Boucher C. A. B., O’Sullivan E., Mulder J. W., Ramautarsine C., Kellam P., Darby G., Lange J. M. A., Goudsmit J., Larder B. A. 1992; Ordered appearance of zidovudine resistant mutations during treatment of 18 human immunodeficiency viruspositive subjects. Journal of Infectious Diseases 165:105–110
   [Google Scholar]
4. Boucher C. A. B., Cammack N., Schipper P., Schuurman R., Rouse P., Wainberg M. A., Cameron J. M. 1993; High-level resistance to ( ― )enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 37:2231–2234
   [Google Scholar]
5. Byrnes V. W., Sardana V. V., Schleif W. A., Condra J. H., Waterbury J. A., Wolfgang J. A., Long W. J., Schneider C. L., Schlabach A. J., Wolanski B. S., Graham D. J., Gotlib L., Quintero J. C., Staszewski S., Emini E. A. 1993; Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrobial Agents and Chemotherapy 37:1576–1579
   [Google Scholar]
6. Byrnes V. W., Emini E. A., Schleif W. A., Condra J. H., Schneider C. L., Long W. J., Wolfgang J. A., Graham D. J., Gotlib L., Schlabach A. J., Wolanski B. S., Blahy O. M., Quintero J. C., Rhodes A., Roth E., Titus D. L., Sardana V. V. 1994; Reverse transcriptase inhibitor susceptibility of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions. Antimicrobial Agents and Chemotherapy (in press)
   [Google Scholar]
7. Chow Y. -K., Hirsch M. S., Merrill D. P., Bechtel L. J., Eron J. J., Kaplan J. C., D’Aquila R. T. 1993a; Use of evolutionary limitations of HIV-1 multi-drug resistance to optimize therapy. Nature; London: 361650–654
   [Google Scholar]
8. Chow Y. -K., Hirsch M. S., Kaplan J. C., D’Aquila R. T. 1993b; HIV-1 error revealed. Nature; London: 364679
   [Google Scholar]
9. Dueweke T. J., Pushkarskaya T., Poppe S. M., Swaney S. M., Zhao J. Q., Chen I. S. Y., Stevenson M., Tarpley W. G. 1993; A mutation in reverse transcriptase of bis(heteroaryl)- piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proceedings of the National Academy of Sciences U.S.A: 904713–4717
   [Google Scholar]
10. Emini E. A., Graham D. J., Gotlib L., Condra J. H., Byrnes V. W., Schleif W. A. 1993; HIV and multidrug resistance. Nature; London: 364679
    [Google Scholar]
11. Eron J. J., Chow Y. -K., Caliendo A. M., Videler J., Devore K. M., Cooley T. P., Liebman H. A., Kaplan J. C., Hirsch M. S., D’Aquila R. T. 1993; pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrobial Agents and Chemotherapy 37:1480–1487
    [Google Scholar]
12. Fitzgibbon J. E., Howell R. M., Haberzettl C. A., Sperber S. J., Gocke D. J., Dubin D. T. 1992; Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrobial Agents and Chemotherapy 36:153–157
    [Google Scholar]
13. Gao Q., Gu Z., Parniak M. A., Cameron J., Cammack N., Boucher C., Wainberg M. A. 1993; The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the ( -)enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents and Chemotherapy 37:1390–1392
    [Google Scholar]
14. Gu Z., Gao Q., Fang H., Salomon H., Parniak M. A., Goldberg E., Cameron J., Wainberg M. A. 1994; Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′- dideoxycytidine and 2′-3′-deoxythiacytidine. Antimicrobial Agents and Chemotherapy 38:275–281
    [Google Scholar]
15. Jacobo-Molina A., Ding J., Nanni R. G., Clark A. D.Jr Lu X., Tantillo C., Williams R. L., Kamer G., Ferris A. L., Clark P., Hizi A., Hughes S. H., Arnold E. 1993; Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3·0Å resolution shows bent DNA. Proceedings of the National Academy of Sciences U.S.A: 903092–3096
    [Google Scholar]
16. Japour A., Chatis P., Eigenrauch H., Crumpacker C. 1991; Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA-RNA hybridization. Proceedings of the National Academy of Sciences U.S.A: 886320–6324
    [Google Scholar]
17. Japour A. J., Mayers D. L., Johnson V. A., Kuritzkes D. R., Beckett L. A., Arduino J. -M., Lane J., Black R. J., Reichel-Derfer P. S., D’Aquila R. T., Crumpacker C. S.Tim RV-43 Study Group & Trm Aids Clinical Trials Group Virology Committee Resistance Working Group 1993; Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrobial Agents and Chemotherapy 371095–1101
    [Google Scholar]
18. Kellam P., Larder B. A. 1994; Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrobial Agents and Chemotherapy 38:23–30
    [Google Scholar]
19. Kellam P., Boucher C. A. B., Larder B. A. 1992; Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proceedings of the National Academy of Sciences U.S.A: 891934–1938
    [Google Scholar]
20. Kellam P., Boucher C. A. B., Tijnagel T. J. G. H., Larder B. A. 1994; Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. Journal of General Virology 75:341–351
    [Google Scholar]
21. Kleim J. -P., Bender R., Billhardt U. -M., Meichsner C., Riess G., Rosner M., Winkler I., Paessens A. 1993; Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrobial Agents and Chemotherapy 37:1659–1664
    [Google Scholar]
22. Kohlstaedt L. A., Wang J., Friedman J. M., Rice P. A., Steitz T. A. 1992; Crystal structure at 3·5Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783–1790
    [Google Scholar]
23. Lacey S. F., Larder B. A. 1994; A mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase significant in nucleoside analogue resistance. Journal of Virology (in press)
    [Google Scholar]
24. Land S., Treloaer G., Mcphee D., Birch C., Doherty R., Cooper D., Gust I. 1990; Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. Journal of Infectious Diseases 161:326–329
    [Google Scholar]
25. Larder B. A. 1992; 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy 36:2664–2669
    [Google Scholar]
26. Larder B. A. 1993; Inhibitors of HIV reverse transcriptase as antiviral agents and drug resistance. In Reverse Transcriptases pp 205–222 Skalka A. M., Goff S. P. Edited by New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
27. Larder B. A., Kemp S. D. 1989; Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:1155–1158
    [Google Scholar]
28. Larder B. A., Darby G., Richman D. D. 1989; HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731–1734
    [Google Scholar]
29. Larder B. A., Kellam P., Kemp S. D. 1991; Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-1 infected lymphocytes. AIDS 5:137–144
    [Google Scholar]
30. Larder B. A., Kellam P., Kemp S. D. 1993; Convergent combination therapy can select viable multidrug resistant HIV-1 in vitro. Nature; London: 365451–453
    [Google Scholar]
31. Mcleod G. X., Mcgrath J. M., Ladd E. A., Hammer S. M. 1992; Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. Antimicrobial Agents and Chemotherapy 36:920–925
    [Google Scholar]
32. Mellors J. W., Im G. -J., Tramontano E., Winkler S. R., Medina D. J., Dutschmam G. E., Bazmi H. Z., Piras G., Gonzalez C. J., Cheng Y. -C. 1993; A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus type 1 confers resistance to ( + )-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3- methyl-2-butenyl)-imidazo [4,5,l-jk]-l,4-benzodiazepine-2(1H)- thione (TIBO, R82150). Molecular Pharmacology 43:11–16
    [Google Scholar]
33. Nunberg J. H., Schleif W. A., Boots E, O’Brien J. A., Quintero J. C., Hoffman J. M., Emini E. A., Goldman M. E. 1991; Viral resistance to human immunodeficiency virus type 1- specific pyridinone reverse transcriptase inhibitors. Journal of Virology 65:4887–4892
    [Google Scholar]
34. Richman D. D., Grimes J. M., Lagakos S. W. 1990; Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes 3:743–746
    [Google Scholar]
35. Richman D. D., Shih C.-K, Rose J., Prodanovich P., Goff S., Griffin J. 1991; Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse tran-scriptase arise in tissue culture. Proceedings of the National Academy of Sciences U.S.A: 8811241–11245
    [Google Scholar]
36. Richman D. D.The ACTG 164/168 Study Team 1993; Nevirapine resistance during clinical trials. Abstracts of the 2nd International Drug Resistance Workshop. Noordwijk, The Nether-lands p 26
    [Google Scholar]
37. Rooke R., Tremblay M., Soudeyns H., Destephano L., Yao J., Fanning M., Montaner J. S. G., O’Shaughnessy M., Gelmon K., Tsoukas C., Gill J., Ruedy J., Wainberg M. A.The Canadian Zidovudine Multi-Centre Study Group 1989; Isolation of drug-resistant variants of HIV-1 from patients on longterm zidovudine therapy. AIDS 3411–415
    [Google Scholar]
38. Saag M. S., Emini E. A., Laskin O. L., Douglas J., Lapidus W. I., Schleif W. A., Whitley R. J., Hildebrand C., Byrnes V. W., Kappes J. C., Anderson K. W., Massari F. E., Shaw G. M.The L-697,661 Working Group 1993; A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. New England Journal of Medicine 3291065–1072
    [Google Scholar]
39. Schinazi R. F., Lloyd R. M.Jr Nguyen M. -H., Cannon D. L., Mcmillan A., Ilksoy N., Chu C. K., Liotta D. C., Bazmi H. Z., Mellors J. W. 1993; Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents and Chemotherapy 37:875–881
    [Google Scholar]
40. St.Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. 1991; Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557–1559
    [Google Scholar]
41. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. 1993; Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences U.S.A.: 905653–5656
    [Google Scholar]
42. Wilde M. I., Langtry H. D. 1993; Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 46:515–578
    [Google Scholar]
43. Zhang D., Caliendo A. M., Eron J. J., Devore K. M., Kaplan J. C., Hirsch M. S., D’Aquila R. T. 1994; Resistance to 2′,3′- dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 38:282–287
    [Google Scholar]